2013-01-18 16:41:13 - New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

High national debt and a falling birth rate create a poor economic outlook and challenging market environment for pharma companies in Italy. Generic penetration is among the lowest in the world. However, as payers seek to control healthcare spending, generic uptake will increase.

Scope

* Analysis of population demographics, economic indicators, and political developments in Italy.
* Insight into the healthcare system, drug regulation, drug pricing, drug reimbursement, and disease burden.
* Evaluation of the generics and biosimilars landscape in terms of regulatory issues, cultural factors, and level of penetration.
* Analysis of the key drivers and resistors of generics and biosimilars markets.


Full Report Details at
- www.fastmr.com/prod/529652_italy_pharmaceutical_market_overview_ ..


Report Highlights

Italy's birth

rate is lower than most other developed European markets. Combined with high national debt, this will result in challenging economic conditions. The greatest impact will be on the market for branded pharma, while generics companies will benefit.

Italy's healthcare spending is comparable with other OECD countries, but lower than the average for France, Germany, Spain, and the UK. Public healthcare accounts for the vast majority of spend, which is delivered through 20 regional health agencies.

Italy has among the lowest levels of generic usage (by both volume and value). Healthcare policy is devolved to regional agencies, which has led to large variation in generic uptake across the country. However, cost-cutting reforms including price cuts have been introduced to increase generic usage nationally.

Reasons to Get this Report

* How is the regulatory landscape in Italy changing and what is the impact of pricing and reimbursement controls on market access?
* What are the drivers and resistors of generic and biosimilars uptake in Italy's pharmaceutical market?
* How have leading pharma companies in Italy been impacted by industry challenges?

Report Table of Contents:

Executive Summary
Healthcare drivers and resistors in Italy
Sociodemographic and Economic Analysis
Key findings
Demographic trends
Disease burden
Political and economic climate
Healthcare System and Drug Regulatory Analysis
Key findings
Healthcare expenditure
Insurance and healthcare system
Regulatory issues
Pricing and reimbursement
Generics and Biosimilars
Key findings
Generics market dynamics
Drivers and resistors in the generics market
Biosimilars market dynamics
Bibliography
Sociodemographic and economic analysis
Healthcare system and drug regulatory analysis
Generics and biosimilars
Appendix
Contributors
Exchange rates used in this report
About Datamonitor
Disclaimer

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.